Autosomal recessive non-syndromic hearing loss (ARNSHL) is a highly heterogeneous genetic condition. PDZD7 has emerged as a new genetic etiology of ARNSHL. Biallelic mutations in the PDZD7 gene have been reported in two German families, four Iranian families, and a Pakistani family with ARNSHL. The effect of PDZD7 on ARNSHL in other population has yet to be elucidated. Two Chinese ARNSHL families, each of which had two affected siblings, were included in this study. The families underwent target region capture and high-throughput sequencing to analyze the exonic, splice-site, and intronic sequences of 128 genes. Furthermore, 1751 normal Chinese individuals served as controls, and 122 Chinese families segregating with apparent ARNSHL, who had been previously excluded for variants in the common deafness genes GJB2 and SLC26A4, were subjected to screening for candidate mutations. We identified a novel homozygous missense mutation (p.Arg66Leu) and novel compound heterozygous frameshift mutations (p.Arg56fsTer24 and p.His403fsTer36) in Chinese families with ARNSHL. This is the first report to identify PDZD7 as an ARNSHL-associated gene in the Chinese population. Our finding could expand the pathogenic spectrum and strengthens the clinical diagnostic role of the PDZD7 gene in ARNSHL patients.
retinas at the age of 15.5 years (Vona et al., 2016) . To date, only seven biallelic mutations of the monogenic PDZD7 have been validated-in two German families, four Iranian families, and a Pakistani family with ARNSHL (Booth et al., 2015; Le Quesne Stabej et al., 2017; Vona et al., 2016) . Outside of the Iranian, German and Pakistani populations, little is known about the effect of PDZD7 on ARNSHL. More reports will be required in order to understand the complete phenotypic spectrum of the PDZD7 gene.
Here, we are the first to show a novel homozygous missense mutation and compound heterozygous frameshift mutations of the PDZD7 gene in two unrelated Chinese families with ARNSHL. Our work could expand the pathogenic spectrum and strengthen our understanding of the mechanism by which PDZD7 causes ARNSHL.
| MATERIALS AND METHODS

| Ethics statement
This study was approved by the Committee of Medical Ethics of Chinese People's Liberation Army (PLA) General Hospital. We obtained written informed consent from all the participants in this study. Written informed consent was obtained from the next of kin on the behalf of the minors/children who participants involved in this study.
| Subjects
Two two-generation Chinese families (CN-0501754 and CN-1507352) with recessive non-syndromic hearing loss (NSHL) were introduced to the Department of Otolaryngology and Head and Neck Surgery at the Chinese People's Liberation Army (PLA) General Hospital. The subjects underwent a full medical history and comprehensive audiological evaluation, including otoscopic examination, pure-tone audiometry, tympanometry, acoustic reflex, distortion product evoked otoacoustic emissions (DPOAEs), and auditory brainstem responses (ABRs).
Temporal bone Computed Tomography (CT) scans were also performed.
The two patients in family CN-1507352 underwent comprehensive ophthalmic evaluation, including visual acuity, direct funduscopy, visual field test, and electroretinogram (ERG) analysis. The proband (II-1) additionally underwent rotational chair testing (RCT) and colic vestibular evoked myogenic potential (cVEMP) testing.
Air conduction (AC) thresholds were bilaterally determined at octave frequencies of 0.25-8.0 kHz. The AC average thresholds at conversational frequencies of 0.5, 1, 2, and 4 kHz were measured and used to define the severity of the hearing loss. Hearing levels were labeled subtle (16-25 dB), mild (26-40 dB), moderate (41-70 dB), severe (71-95 dB), or profound (95 dB) (Kim et al., 2015) .
| Targeted gene capture and high throughput sequencing
Genomic DNAs of the probands, their brothers, and parents were extracted from peripheral blood samples using the Blood DNA kit (TIANGEN BIOTECH, Beijing, China).
Targeted gene capture and high throughput sequencing have been described in detail previously (Wang et al., 2014) . In brief, we used a targeted genomic enrichment platform to simultaneously capture exons, splicing sites and immediate flanking intron sequences of 128 known deafness genes (Supplementary Table S1 ). The probands underwent targeted region sequencing, which built the DNA library.
Universal primers for PCR amplification were adopted, after which sequencing of the PCR products was carried out on an Illumina HiSeq 2000 (San Diego, CA). The test platform examined >95% of the target gene with a sensitivity of >99%. Point mutations, micro-indels, and duplications (<20 bp) could be detected simultaneously. The data were not analyzed for copy number variants (CNVs).
| Mutation analysis and control screening
Sanger sequencing was used to identify participants segregating causative variants in the candidate gene. PCR was performed with a PE9700 thermocyclers (Applied Biosystems, Foster City, CA).
Sequence analysis was performed on an automated sequencer (ABI 3730, Applied Biosystems) for both affected and normal individuals. In family CN-0501754, the affected siblings ( Figure 1b , II-1, 2)
were an 11-year-old girl and an 8-year-old boy. They showed bilaterally symmetrical mild hearing loss at 250 Hz and moderate hearing loss between 500 and 8000 Hz. Individual II-1(11y) show slightly worse hearing than II-2(8y). They exhibited normal latency and amplitude of ABR waves I, III, and V (Figures 1d and 1f) .
Temporal bone CT scans were normal in subject II-1. A telephone follow-up call was immediately conducted after we identified the disease-causing gene. The affected members (Figure 1b Tables S3 and S4) . We further performed in silico analyses, and a missense variant, c.197G>T in exon 2 of PDZD7 was predicted to be "Deleterious" by SIFT, "Probably damaging" by PolyPhen, "Conserved" by GERP++ and Phylop software (Table 1) .
These results indicated that this novel mutation could be the cause of the hearing loss in this Chinese family. Sanger sequencing revealed that the mutation segregates with the phenotype, and unaffected parents were heterozygous carriers (Figures 1a and 2a) .
Subsequently, for the proband of another family (CN-0501754), a total of 298 variants were identified, 176 of which were nonsynonymous variants, splice acceptor and donor site mutations, and coding indels that were more likely to be pathogenic mutations; only 8of the 176 coding variants were an allele frequency of less than 0.01 in the 1000 human genome and local dataset. Two heterozygous variants leading to amino acid change were detected in (p.R66L) occurs at highly conserved residues (Figure 2c , Table 1 ).
3.3 | Molecular structural modeling of the R66L amino acid substitution A 3D structural model of PDZD7 was predicted with SWISS-MODEL to determine whether the novel p.R66L missense mutation in an ARNSHL Chinese family affects the structure of PDZD7. The sequence identity between the target and template was 26.59%. The R66L molecular model covered the target sequence of PDZD7
(residues 4-294). Using Swiss-Pdb Viewer 4.1, the mutation was predicted to result in the loss of an H-bond between Arg 66 and Met 64 due to the substitution of arginine to leucine at position 66, possibly perturbing the amino acid side chain (Figure 3 ).
| DISCUSSION
PDZD7 encodes a PDZ domain-containing scaffold protein; the largest transcript (NM_001195263.1) of PDZD7 encodes 17 exons, and it has been implicated as an ARNSHL-associated gene (Booth et al., 2015; Le Quesne Stabej et al., 2017; Schneider et al., 2009; Vona et al., 2016) and a modifier and candidate gene for human USH2 (Ebermann et al., 2010) . In this study, next generation sequencing (NGS) was used to find the disease-causing gene of two Chinese families with ARNSHL ( Figure 1a and 1b) , and we identified two biallelic mutations in the PDZD7 gene. Furthermore, we determined that the both biallelic mutations are causative. This prediction was supported by the fact that the mutation co-segregated with the disease status. PDZD7 mutations Table 2 . Of our two families, one showed a novel homozygous missense mutation (c.197G>T, p.Arg66Leu), and the other a compound heterozygous frameshift mutation (c.166_167insC, p.
Arg56Profs*24, and c.1207delC, p. His403Ilefs*36). PDZD7 is expressed in the stereocilia ankle-link region of the mechanosensitive structure. The PDZD7 protein localization at the connecting cilium region has been shown to play a role in inner ear hair cell development (Ebermann et al., 2010) . In mice, the abnormal expression of the Pdzd7gene causes disorganization of hair bundles and may affect the establishment of mechanotransduction responses, which likely results in hearing loss (Zou et al., 2014) . PDZD7 is a three-PDZ domain protein with a central prolinerich region. Multi-PDZ domain-containing scaffolds could play a complementary role in the structure of the ankle-links for the mutant type (Grati et al., 2012) . The three mutations of our study lie outside In addition, PDZD7 is a member of the Usher quaternary protein complex (PDZD7, USH2A, GPR98 and WHRN), and localization in the ankle-link makes it a good candidate for Usher syndrome type 2 (USH2) (Chen, Zou, Shen, Zhang, & Yang, 2014; Zou et al., 2014) . USH2
is the most common Usher syndrome type. USH2 patients present with congenital moderate to severe hearing loss, retinitis pigmentosa (RP), and normal vestibular function. RP usually develops from the second decade onwards (Besnard et al., 2012; Chen et al., 2014) . Early symptoms of RP include night blindness and loss of peripheral vision.
However, to date, only monoallelic mutations in the PDZD7 gene act as a retinal disease modifier of homozygous USH2A mutations and a contributor of digenic inheritance with GPR98 in USH2 patients (Ebermann et al., 2010) . The PDZD7 mutation p.Arg56Profs*24 (c.166_167 insC) was suggested to be a retinal phenotype modifier in Usher syndrome in its heterozygous state. No biallelic mutations of PDZD7 were found in USH2 (Aparisi et al., 2014; Besnard et al., 2012) .
In this study, we did not find other functional candidate gene variants of classical Usher syndrome genes by targeted region capture and high throughput sequencing. At present, the oldest patient reported with ARNSHL-associated PDZD7 biallelic mutations is 38 years old (Table 2) , and this patient showed no abnormalities in funduscopy (Booth et al., 2015) . In our study, the age of the ARNSHL affected individuals was plays a limited role in localizing USH2 proteins in photoreceptors (Zou et al., 2014) . Overall, our data support the contribution of PDZD7 biallelic mutations to the etiology of ARNSHL in humans.
This is the first study to identify PDZD7 as an ARNSHL-associated gene in the Chinese population. The study is significant because it leads to a better understanding of PDZD7 biallelic mutations on phenotypic outcome and strengthens the clinical diagnostic role of the PDZD7 gene in ARNSHL patients.
